A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site - Test2 - elhamkhani - TriplyDB

A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site

A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site

http://www.wikidata.org/entity/Q28323713

about

Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors Specific HIV-1 reverse transcriptase inhibitors Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy Anti-(human immunodeficiency virus) activity of polyoxotungstates and their inhibition of human immunodeficiency virus reverse transcriptase A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analo Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.Domain structure of the human immunodeficiency virus reverse transcriptase.Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.The role of nevirapine in the treatment of HIV-1 disease.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription Antiviral therapy for human immunodeficiency virus infections Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase.Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis.New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: sensitivity/resistance of HIV-1 to non-nucleoside HIV-1-specific inhibitors.Effect of template secondary structure on the inhibition of HIV-1 reverse transcriptase by a pyridinone non-nucleoside inhibitor Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.Cystatins in health and disease.

P2860

Q27729365-691DCF86-2C66-44E1-B3EC-1A90E21067B7 Q28316183-C6C2EA2F-F85F-4363-9E4F-DF9E64588B15 Q28316336-9E571B29-F014-4362-80AE-42E73DA577E8 Q28324145-021CC478-2439-4601-84A5-73EDA472BEF8 Q28324214-45C1C49B-932A-4EDE-8D01-0D1DEBB42775 Q28342745-EDF617EE-7EE0-4C99-B8F2-697016D61C46 Q28342783-FE6E67A1-06B3-4938-A504-073301B1FFDD Q28343606-F93D1A9F-B425-4930-BA7E-77340E0A5A97 Q28367526-6F34940D-9436-4CA7-BB18-DBB6F8C86904 Q28367667-F533D4C5-B8CF-4129-940B-E77B56E68224 Q28368028-D8158FD3-1777-4D5D-986A-1B853EA7B493 Q28368034-74D3EBB9-CA50-4529-B67F-001116F3791C Q28368045-12FB9AA5-8489-494E-B6FE-E49A358FAD49 Q28368052-B9E338E2-DFC3-4328-B27A-E57764D8AEA4 Q28368053-4C039EDF-94C4-4580-A335-34E21EA407A3 Q28378547-90773C33-0DD7-4963-A337-685E48CF20D5 Q28378789-57EF6882-8310-4B9C-AC90-485D3E8D6457 Q28378796-B8DB19C7-A62C-401D-BE90-72673CB0565D Q28379406-24F19251-8258-424E-8AEB-103286BDC59D Q28379523-2D103CAD-3613-438B-9C3F-7C87533DDA1B Q28478130-FCD1B9EE-2F1F-487B-9B41-564DBBB45927 Q33535654-A8599AC0-E37D-4B30-A064-B4F2533DB15C Q33937534-0803883F-0F1A-4F5F-9724-D082ECB2540E Q34181367-158BCAF4-FE7B-4CAC-8FAE-E01AF1D8F254 Q34515604-7E76DE1B-55C8-49C3-9386-7B7BFD5DEB95 Q35122784-D8A56793-0276-4A6B-ABD7-12680966DA23 Q35366050-E2216909-9690-42AE-B26C-7008366F65AC Q35623899-780B1104-2B90-43A0-B1BF-E1E33FA44C27 Q35636068-3506ED8B-4C26-4172-9745-22A45F4C6A7D Q35859433-33EC3EBC-B153-4824-B89E-C92B41FFD3F4 Q36651931-9AF3F607-DFED-4173-A886-C8DD2EB21A60 Q38297932-C92BCD3D-FBA9-40F9-B22B-4AC43DD48C45 Q38298830-A4056299-D747-4F7F-9D43-7363000F88C1 Q38351813-D666B44D-8FF3-49B3-9315-8584F447ED70 Q39699409-FEEF1BBA-3BBD-4D9C-A043-6D8090EB6B10 Q40065525-4B8629D4-CDDA-461C-938B-8CD876272C97 Q40390744-9619952B-CBAC-4DA7-A02F-1745C2C2B455 Q40399390-6D703670-DFE9-45DE-A48B-A53A64457D70 Q40504294-CD9E3302-BAA7-4DEF-8F7A-0273A597445C Q41161690-6D4B3EF0-EE5F-42E6-B9AE-48BC1CE1D958

P2860

A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site

http://www.wikidata.org/entity/Q28323713

description

1991 nî lūn-bûn

@nan

1991 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@ast

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@en

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@nl

type

label

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@ast

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@en

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@nl

prefLabel

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@ast

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@en

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@nl

P1433

Q28323713-820ACBC5-D473-45DC-9D9B-47C340B56B8C

P1476

Q28323713-B682232E-A48A-4073-A5AF-9912ECCBF58B

P2093

Q28323713-0DF75EA5-DA41-4DC9-92EC-3A885B302763

Q28323713-4072E5C4-FDA1-4091-94E2-EE82F2A5162E

Q28323713-42361DD2-E314-4FAB-A24B-DAE99E6E8B02

Q28323713-4883C3A0-B3A7-4BED-877B-D2CF807F2DF8

Q28323713-717D1BAF-499A-443D-94B9-AC2116A9E2FC

Q28323713-B3E13454-EC5E-4F80-8DB9-C9960E84195A

Q28323713-B55D7D03-9806-4F52-899D-28AD6AEBE57C

Q28323713-EB6A70AA-84E7-4330-99A5-A95AE5E30EF0

Q28323713-F1F7F5AC-F6B2-4E54-B4D9-E9D42214424C

Q28323713-FC3F14F7-10A8-42F3-A8E9-C38B6EA38789

P304

Q28323713-B6611784-5A6F-41B2-AB88-FA478E018CAD

P31

Q28323713-7CA1D767-7E6D-43D6-81DD-4324A552F6FB

P356

Q28323713-FECE3E0F-B1CA-4025-81E2-6878DA1658FA

P407

Q28323713-0CA9BE3D-84F0-4734-A8D9-BFA1C5967855

P433

Q28323713-1BC32995-D0A5-4961-80D3-48C18814AB81

P478

Q28323713-6C2D0E9A-8B35-446E-9363-FE1A9E45FDB8

P577

Q28323713-239A377C-E4EA-4876-B98F-07B3DE81DB28

P698

Q28323713-DD1BB0EC-7037-4039-82E7-DDAA0EE1B5E6

P356

P1433

P1476

A novel dipyridodiazepinone in ...... gh a nonsubstrate binding site

@en

P2093

C Perry

http://www.w3.org/2001/XMLSchema#string

I Potocki

http://www.w3.org/2001/XMLSchema#string

J Adams

http://www.w3.org/2001/XMLSchema#string

J C Wu

http://www.w3.org/2001/XMLSchema#string

J Proudfoot

http://www.w3.org/2001/XMLSchema#string

J Skiles

http://www.w3.org/2001/XMLSchema#string

P M Grob

http://www.w3.org/2001/XMLSchema#string

P R Farina

http://www.w3.org/2001/XMLSchema#string

P Raghavan

http://www.w3.org/2001/XMLSchema#string

T C Warren

http://www.w3.org/2001/XMLSchema#string

P304

2022-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BI00222A003

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

1991-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1705436

http://www.w3.org/2001/XMLSchema#string